Allergan, Inc., (NYSE:AGN) has announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21.

Allergan conducted a pivotal clinical trial in the United States and Canada for submission to the FDA. The trial demonstrated that Juvederm Voluma™ XC was an effective treatment compared to the control group, which did not receive treatment.

Juvederm Voluma™ XC is made with Allergan’s proprietary VYCROSS™ technology, an advanced manufacturing process that results in a smooth gel that flows easily and consistently.

Read the full news story here.